

Index

a

- 2:1 atrioventricular block
 - atrial utter 114–115
 - evaluation 79, 81
 - supraventricular tachycardia 111
- AAI pacing modes 98–99, 105–106
- ablation therapy 221–318
 - atrial brillation 161, 279–299
 - carina 286, 287
 - cryoballoons 295–298
 - drug testing 289–290
 - history 279–280
 - left-sided 284–285
 - mapping 282
 - post-operative electrograms 288–289
 - preparation 281
 - pulmonary vein isolation 281–298
 - repeat procedures 290–295
 - right-sided 285–287
 - substrate modification 298
 - transseptal puncture 283
 - atrial utter 299–318
 - anterior wall left-sided 315–316
 - CTI-dependent 303–306
 - de novo* left-sided 316–317
 - left-sided 309–317
 - non-CTI-dependent 306–317
 - peri-mitral 311–313
 - right-sided 306–309
 - roof-dependent left-sided 313–315
 - bypass tracts 241–253
 - location-based approaches 246–253
 - mapping 241–246
 - complications 231
 - cryo 224, 295–298
 - direct-current shocks, technology 222
 - electrical field mapping 228
 - focal atrial tachycardias 254
 - intraatrial reentrant tachycardias 156
 - macroreentrant tachycardias 153, 155
 - location-based approaches 246–253
 - mapping 241–246
 - magnetic field mapping 226–228

Fogoros' Electrophysiologic Testing, Sixth Edition. Richard N. Fogoros and John M. Mandrola.

© 2018 John Wiley & Sons Ltd. Published 2018 by John Wiley & Sons Ltd.

- ablation therapy (*Continued*)
 - mapping systems 225–231
 - noncontact mapping 228–230
 - principles 34–35
 - radiofrequency energy
 - complications 231
 - technology 223–224
 - supraventricular tachycardia
 - 233–254
 - atrioventricular junction
 - 233–234
 - atrioventricular node reentry
 - 234–241
 - bypass tracts 241–253
 - focal atrial tachycardias 254
 - technology 221–224
 - ventricular tachycardia 209, 255–278
 - activation mapping
 - 256–258, 270
 - bundle branch reentry
 - 264–266
 - complications 277
 - epicardial sinus 259, 276–278
 - hemodynamically
 - non-tolerated 274–277
 - idiopathic left ventricular tachycardia 262–264
 - non-ischemic cardiomyopathies
 - 275–276
 - outflow tract anatomy
 - 258–259
 - pace mapping 258, 271–274
 - structural heart disease
 - 266–274
- accelerated junction tachycardia, atrioventricular node ablation 240
- accuracy, radiofrequency ablation 224
- N*-acetylprocainamide 29
- action potentials
 - see also* electrical impulses
 - afterdepolarization 21–23
 - antiarrhythmic drugs 5, 25–29
 - automaticity 8–9
 - AV node 4–5, 8–9
 - bradyarrhythmias 14–16
 - cardiac anatomy 3–12
 - depolarization 6–7, 11
 - ECG correlation 11–12, 43
 - generation 5–11
 - para/sympathetic regulation 11
 - phases 6–9
 - propagation 3–5, 7, 11–12
 - refractory period 6, 7–8
 - repolarization 7–8, 12
 - resting phase 8–9
 - SA node 3–4, 9
 - shapes 5, 9–12, 25–27
 - tachyarrhythmias 16–17
- activation mapping
 - focal atrial tachycardias 254
 - ventricular tachycardia 256–258, 270
- AFFIRM trial 162–163
- afterdepolarization
 - delayed 200–202
 - early 197–200
 - triggered activity 21–23
- AH intervals, principles 50, 54–55
- ambulatory monitoring, syncope 337, 344
- amiodarone 28, 29, 32–33, 204, 207–208

- anatomic approach, reentrant
 - atrioventricular node ablation 240
- anatomy
 - atrioventricular node 4–5, 234–238
 - bundle of His 4–5
 - cardiac 3–5, 11
 - CTI-dependent utter 299–302
 - sinoatrial node 3–4, 64
- anesthesia 47
- anterior septal bypass tracts 147–148, 242, 252–253
- anterior wall left-sided atrial utter ablation 315–316
- anterograde conduction, bypass tracts 143, 146, 152–153
- antiarrhythmic drugs 25–33
- atrial brillation 160–163
- catechol-dependent triggered activity 202
- classi cation 27–29
- ects 29–31
- inappropriate sinus tachycardia 111
- intraatrial reentry 114, 156
- macroreentrant tachycardia 150
- mechanisms 25–27
- patient evaluation 61
- pause-dependent triggered activity 199
- physiological e cts 5
- proarrhythmia 31–32
- pulmonary vein isolation 289–290
- reentrant ventricular tachycardias 189–190, 192–194
- side e cts 34
- toxicity 32–33
- triggered activity 22–23
- vasodepressor syncope 342
- ventricular tachycardia 192–194, 199, 202, 217–219, 255
- vs. implantable cardioverter–de brillators 189
- withdrawal 33–34
- antitachycardia pacing (ATP) 194–196
- anxiety management 47
- arterial lesion risks 231
- A spikes 50, 54–55
- atria, electrode placement 48–49
- atrial activation, bypass tract-mediated reentry 146–148
- atrial brillation
 - ablation therapy 279–298
 - carina 286, 287
 - catheterization 281–282
 - cryoballoons 295–298
 - drug testing 289–290
 - history 279–280
 - left-sided 284–285
 - mapping 282
 - post-operative electrograms 288–289
 - preparation 281
 - pulmonary vein isolation 281–298
 - repeat procedures 290–295
 - right-sided 285–287
 - substrate modi cation 298
 - transseptal puncture 283

- atrial brillation (*Continued*)
 - antiarrhythmic drugs 160–163
 - brady-tachy syndrome 65–66
 - bypass tracts 151–153
 - diagnosis 114–115, 151–153, 159–160, 354
 - pacemakers 161
 - rate control 161–163
 - rhythm control 160–161, 162–163
 - risk factors 298
 - substrate modifications 298
 - supraventricular tachycardia 114–115, 151–153, 160–163
- atrial brosis, brady-tachy syndrome 65–66
- atrial utter
 - ablation therapy 299–318
 - anterior wall left-sided 315–316
 - CTI-dependent 303–306
 - de novo* left-sided 316–317
 - left-sided 309–311
 - non-CTI-dependent 306–317
 - peri-mitral 311–313
 - right-sided 306–309
 - roof-dependent left-sided 313–315
 - bypass tracts 151–153
 - CTI-dependent 299–306
 - non-CTI-dependent 306–317
 - supraventricular tachycardia 114–115, 151–153, 157–159
- atrial muscle, stereotypical action potential 9
- atrial tachycardia
 - automatic 108
 - digitalis toxicity 108–109
 - multifocal 109
- atrial tachycardias, ablation therapy 254
- atrioventricular (AV) block
 - atrial utter and brillation 114–115, 161
- bradycardia
 - evaluation 75–93
 - rst-degree 76–77, 83–84
 - His-Purkinje block 76, 85–86
 - inapparent disorders 86–93
 - localization 75–80, 81–86
 - nodal block 75–76, 84–85, 86
 - overt disorders 83–86
 - recording 83
 - second-degree 77–79, 84–86
 - symptoms 75
 - third-degree 79–80, 86
 - treatment 80–81
- classifications 14–16
- extrastimulus technique 87–91
- incremental pacing 91–93
- macroreentrant tachycardia
 - treatment 148–150
- permanent pacemakers 96
- supraventricular tachycardia 111, 114–115, 148–150
- syncope 335
- atrioventricular (AV) bypass tracts 138–139
- atrioventricular (AV) conduction curves 146–147
- atrioventricular (AV) dissociation 79–80

- atrioventricular (AV) groove
 - 4–5, 138–141, 151
- atrioventricular (AV) nodal
 - reentrant tachycardia
 - 112–114, 129–138
 - ablation therapy 234–241
 - activation patterns 134–135
 - atypical 137
 - diagnosis 164–165
 - initiation 131–133
 - mechanisms 129–131
 - myocardial involvement
 - 135–136, 148
 - properties 112–113, 136
 - P wave/QRS complex
 - relationships 136
 - termination 133–134
 - treatment 137–138
- atrioventricular (AV) node
 - ablation therapy 233–241
 - anatomy 4–5, 234–238
 - bradycardia 75–76, 84–85, 86
 - extrastimulus technique
 - 87–91
 - incremental pacing 91–93
 - bypass tracts 138–139,
 - 153–155
 - conduction velocities 54–55
 - dual pathways 233–238
 - electrode placement 50–51
 - electrograms 50, 54–55
 - first-degree blocks 76–77,
 - 83–84
 - heart block 14–15
 - Koch's triangle 236–237
 - macroreentrant tachycardia
 - 113–114, 148–150
 - permanent pacemakers 96
 - secondary pacemaker cells
 - 8–9
 - second-degree blocks 77–79,
 - 84–86
 - slow pathway ablation
 - 237–241
 - stereotypical action potential 9
 - third-degree blocks 79–80, 86
- automatic atrial tachycardia,
 - properties 108
- automaticity
 - antiarrhythmic drugs 29
 - bradyarrhythmias 13–14,
 - 66–70
 - principles 8–9
 - programmed stimulation 44
 - tachyarrhythmias 16–17, 53
- automatic supraventricular
 - tachycardia
 - classification 108–111
 - inappropriate sinus tachycardia
 - 109–111, 114
- automatic tachyarrhythmia
 - mechanisms 16–17
- automatic ventricular
 - tachyarrhythmia 61,
 - 196–202
 - catechol-dependent 61,
 - 200–202, 205
 - pause-dependent 197–201
 - post-myocardial infarction
 - 196–197
- autonomic tone
 - AV block diagnosis 81–82
 - intrinsic heart rate 73–74
 - physiological effects 58
 - reentrant arrhythmia effects
 - 61
- AV *see* atrioventricular
- AV intervals, cardiac
 - resynchronization
 - therapy 329–330

b

- baseline recordings 51–52, 116–117
- basic cycle length (BCL) 60
- basic protocol 51
- Baye's theorem 185–186
- BCL *see* basic cycle length
- β-blockers 61
 - atrial brillation 161
 - catechol-dependent triggered activity 202
 - inappropriate sinus tachycardia 111
 - macroreentrant tachycardia 148, 153
 - principles 29
 - sinoatrial node reentrant tachycardia 114
 - ventricular tachyarrhythmias 202, 204, 219
- bilateral fascicular block 96
- binding, Class I drugs 25–27
- bipolar recording configuration 42
- blanking periods, pulmonary vein isolation 291
- Bovie machines 223
- bradyarrhythmias 13–16, 63–106
 - atrioventricular conductivity 75–93, 335
 - distal block 76–79, 81
 - disturbance sites 75–79, 81–83
 - extrastimulus technique 87–91
 - rst-degree block 76–77, 83–84
 - incremental pacing 91–93
 - second-degree 77–79, 84–86
 - third-degree 79–80, 86
 - bundle branch block 93–97
 - cardiac resynchronization therapy 95, 97, 100–101
 - His–Purkinje system 76, 85–86, 93–96
 - impulse generation 13–14
 - impulse propagation 14–16
 - intraventricular conduction delay 94
 - mechanisms 13–16
 - Mobitz-type I blocks 77–79, 84–86
 - Mobitz-type II blocks 77–79, 85–86
 - permanent pacemakers 96–106
 - complications 101–105
 - decisioning 81, 105–106
 - major indications 96–97
 - modes 98–101
 - nomenclature 97
 - sinoatrial node 64–74, 334–335
 - dysfunctions 64–66
 - interpretation 74
 - SACT 70–73
 - SNRT 66–70
 - syncope 334–335
- brady-tachy syndrome 64, 65–66
- Brugada syndrome 204–205
- bundle branch block 93–97, 148, 202–204
 - Mahaim tracts 248–250
 - posterior septal bypass tracts 251
- reentrant ventricular tachycardia 264–266

- bundle of His
 - anatomy 4–5
 - electrode placement 50–51
 - bypass tract-mediated
 - macroreentrant tachycardia 113–114, 138–155
 - ablation therapy 241–253
 - location-based approaches 246–253
 - mapping 241–246
 - activation patterns 146–148
 - atrial utter and brillation 151–153
 - atrioventricular node 113–114, 148–150
 - diagnosis 118, 146–148, 151, 164, 165
 - initiation 143–146
 - mechanisms 138–143
 - myocardial involvement 148
 - preexcitation 139–141
 - P wave/QRS complex
 - relationships 143–144, 148
 - termination 146
 - treatment 148–155
- bypass tracts
 - anterior septal 147–148, 242, 252–253
 - anterograde conduction 143, 146, 152–153
 - atrioventricular nodal 138–139, 153–155
 - characteristics 241
 - concealed 143–146
 - delta waves 242–243
 - electrocardiograms 143–144, 148, 241–243, 252–253
 - fasciculoventricular 154
 - intracardiac electrograms 244–246
 - left-sided 147, 242, 246–247
 - Mahaim-type 138–139, 154, 248–250
 - midseptal 242, 252–253
 - multiple 154–155
 - posterior septal 242, 250–251
 - properties 138–141, 151
 - retrograde conduction 143–148, 150
 - right-sided 147, 242, 247–248
 - surgical treatment 155, 241–253
- C**
- calcium blockers
 - atrial brillation 161
 - inappropriate sinus tachycardia 111
 - calcium ion channels
 - antiarrhythmic drugs 25–29
 - automaticity 8–9
 - depolarization 5, 6–7
 - cardiac action potentials 5–12
 - afterdepolarization 21–23
 - antiarrhythmic drugs 25–29
 - automaticity 8–9
 - bradyarrhythmias 14–16
 - depolarization 6–7, 11
 - ECG correlation 11–12
 - generation 5–11
 - para/sympathetic regulation 11
 - phases 6–9
 - propagation 3–5, 7, 11–12
 - repolarization 7–8, 12
 - resting phase 8–9
 - shapes 5, 9–12, 25–27
 - tachyarrhythmias 16–17

- cardiac anatomy 3–5, 11
- Cardiac Arrhythmia Suppression Trial (CAST) 206–207
- cardiac cells 6, 8–9
- cardiac electrical system 3–12
- cardiac resynchronization therapy (CRT) 95, 97, 319–332
 - clinical studies 323–326
 - contractility 322–323
 - effects 322–323
 - hemodynamic stabilization 322
 - implantation 327–328
 - indications 326–327
 - optimization 329–331
 - pacing modes 100–101
 - principles 320–322
 - reverse remodeling 323
 - unresolved issues 328–329
- carina, pulmonary vein isolation 286, 287
- CARTO mapping system 226–228, 230
- CAST *see* Cardiac Arrhythmia Suppression Trial
- catecholamine-dependent ventricular tachycardia 61, 200–202, 205
- catheterization
 - atrial brillation ablation 281–282
 - complications 62
 - positioning 47–51
 - radiofrequency ablation 223–224
 - reentrant supraventricular tachycardia diagnosis 116–117
- cavo-tricuspid isthmus (CTI)-dependent utter 299–306
- cellular potentials 5–6
 - automaticity 8
 - depolarization 6–7
 - quiescence 8
 - refractory period 6–8
 - repolarization 7–8
 - resting phase 8–9
- chaotic atrial tachycardia *see* multifocal atrial tachycardia
- circuits, reentry 18–21
- Class Ia drugs 27–29
 - binding 25–27
 - intraatrial reentry 114, 156
 - macroreentrant tachycardia 150, 153
- Class Ib drugs 29
- Class Ic drugs 29
 - inappropriate sinus tachycardia 111
 - macroreentrant tachycardia 150
- Class II drugs 28–29
 - see also* β -blockers
- Class III drugs 28–29
- Class IV drugs 28–29
- Class V drugs 28–29
- classi cations
 - antiarrhythmic drugs 27–29
 - automatic supraventricular tachycardia 108–111
 - heart block 14–16
 - permanent pacemakers 97
 - reentrant supraventricular tachycardias 111–116
- compact atrioventricular node 233–238

- complications 62
 - direct current ablation 222
 - implantable cardioverter–de brillators 210–211
 - radiofrequency ablation 231
 - reentrant atrioventricular nodal treatment 237–238
 - ventricular tachycardia ablation 277
 - concealed bypass tracts 143–146
 - conduction velocities
 - autonomic tone 58
 - evaluation 43–45, 54–55, 57–58
 - functional refractory periods 57
 - principles 9
 - reentry 18–21
 - relative refractory periods 56
 - sinoatrial node 70–74
 - supraventricular reentry 118–125
 - conductivity
 - anterograde 143, 146, 152–153
 - AV node and bradycardia 75–93
 - His bundle evaluation 54–55
 - reentry 18–21
 - retrograde 143–148, 150
 - congenital reentrant pathways 20
 - construction of electrode catheters 41–42
 - contractility, cardiac
 - resynchronization therapy 322–323
 - coronary sinus
 - peri-mitral atrial utter 311
 - posterior septal bypass tracts 251
 - ventricular tachycardia 259
 - corrected sinus node recovery time (CSNRT) 69–70
 - coupling intervals
 - functional refractory periods 57
 - principles 40–41
 - supraventricular tachycardia 120
 - CRT *see* cardiac resynchronization therapy
 - cryo ablation
 - atrial brillation 295–298
 - technology 224
 - CSNRT *see* corrected sinus node recovery time
 - CTI *see* cavo-tricuspid isthmus
 - cumulative risk 62
 - cycle length
 - concepts 40
 - refractory period effects 57–58
 - Wenckebach 91
- d**
- DADs *see* delayed afterdepolarizations
 - DC *see* direct current
 - DDD pacing modes
 - decisioning 105–106
 - inappropriate rate tracking 103
 - principles 99–100
 - tachycardia induction 101–103
 - decisioning
 - pacemaker choice 81, 105–106
 - supraventricular tachycardia testing 163–166

382 | Index

- de brillation 45–46, 47, 187
 - see also* direct current cardioversion
- De brillator in Acute Myocardial Infarction Trial (DINAMIT) 214–216
- degeneration, reentrant ventricular tachycardias 188
- delayed afterdepolarizations (DADs) 200–202
- delta waves 139–141, 242–243
- de novo* left-sided atrial flutter 316–317
- depolarization
 - see also* afterdepolarization
 - class I drugs 25–29
 - intracardiac electrogram data 42–43
- depressed ejection fractions, reentrant ventricular tachyarrhythmias 173–175
- designing treatment plans 354–357
- device therapy
 - atrial brillation 161
 - AV block efficacy 81
 - cardiac resynchronization 319–332
 - clinical studies 323–326
 - effects 322–323
 - implantation 327–328
 - indications 326–327
 - optimization 329–331
 - principles 320–322
 - complications 101–105
 - decisioning 81, 105–106
 - leadless 104–105
 - macroreentrant tachycardias 150
 - principles 35
 - rate tracking 103
 - reentrant ventricular tachycardias 194–196
 - ventricular dyssynchrony 103–104
- diagnosis
 - see also* differential diagnosis
 - antiarrhythmic drugs 61
 - atrial brillation 114–115, 151–153, 159–160, 164, 354
 - atrioventricular block 75–93
 - automaticity evaluation 53
 - bundle branch block 93–97
 - bypass tracts 241–246, 252–253
 - cardiac electrophysiology evaluation 52–61
 - cardiac resynchronization therapy 326–327, 329–331
 - conduction velocities 54–55, 57–58
 - cumulative risk 62
 - equipment 41–42, 45–46
 - extrastimulus technique 44–45
 - incremental pacing 44
 - intrinsic heart rate 73–74
 - laboratory requirements 45–46
 - left bundle branch block 95–97
 - macroreentrant tachycardia 118, 146–148, 151, 164, 165
 - mapping, principles 60–61

- methodology 347–353
- pacing 43–45
- patient preparation 46–47
- permanent pacemakers
 - 96–106
- positioning of electrodes
 - 47–51
- principles 39–62
- programmed stimulation
 - 43–45
- recording 43–45, 60–61
- reentrant disorders 58–61,
 - 118–125, 146–148, 151
- refractory periods 55–58
- right bundle branch block
 - 94–95
- sinoatrial node 64–74
- syncope 338–341, 342–345
- therapeutic end points
 - 353–354
- treatment plans 354–357
- di erential diagnosis
 - anterior/midseptal bypass tracts
 - 252–253
 - posterior septal bypass tracts
 - 251
 - supraventricular tachycardia
 - 118–129, 163–166
 - ventricular tachycardia
 - 178–179
- digitalis 29
 - atrial brillation 161
 - macroreentrant tachycardia
 - 153
 - toxicity 108–109, 111
 - triggered activity 22–23
- DINAMIT *see* De brillator in Acute Myocardial Infarction Trial
- direct current (DC) ablation,
 - technology 222
- direct current (DC) cardioversion
 - 187
 - see also* de brillation
- directionality
 - ECGs 10, 11–12
 - intracardiac electrogram data
 - 42
 - reentry 18–21
- dissociation, atrioventricular
 - 79–80
- distal heart block 76–79
 - see also* Mobitz-type II blocks
 - rst-degree 83–84
 - pacemakers 81
- dose–response curves, inducibility
 - 191–194
- dual atrioventricular nodal
 - pathways 233–238
- dual-chambered pacemakers
 - 99–100
- “dunk-tank model” 192–194
- dysautonomia, inappropriate
 - sinus tachycardia
 - 110–111
- dysplasia, right ventricular
 - 203
- e**
 - EADs *see* early afterdepolarizations
 - early afterdepolarizations (EADs)
 - 197–200
 - ECG *see* electrocardiograms
 - echo zones *see* tachycardia zones
 - EEG *see* electroencephalograms
 - e ctive refractory periods (ERP)
 - 56, 58–60, 87–91
 - electrical eld mapping 228

- electrical impulses
 - see also* action potentials; conduction...
 - afterdepolarization 21–23
 - anterograde 143, 146, 152–153
 - antiarrhythmic drugs 5, 25–29, 61
 - AV node 3–4
 - baseline recordings 47, 51–52
 - bradyarrhythmias 14–16
 - cardiac anatomy 3–12
 - depolarization 6–7, 11
 - ECG correlation 11–12
 - para/sympathetic regulation 11
 - physiological evaluation 52–61
 - propagation 3–5, 7, 11–12
 - reentry 18–21
 - refractory period 6, 7–8
 - repolarization 7–8, 12
 - resting phase 8–9
 - retrograde 143–148, 150
 - SA node 3–4
 - tachyarrhythmias 16–17
- electrical system
 - ECG correlation 11–12
 - innervation 11
 - physiological evaluation 52–61
 - principles 3–12
- electroanatomic mapping systems 225–231
 - electric eld mapping 228
 - magnetic eld mapping 226–228
 - noncontact systems 228–230
 - principles 225–226
- electrocardiograms (ECG)
 - see also* intracardiac electrograms
 - action potentials relationship 11–12, 43
 - atrial brillation 114–115, 152, 164
 - atrial utter 114–115, 164
 - atrioventricular node reentry 136, 164
 - automatic atrial tachycardia 108, 164–165
 - AV block diagnosis 81
 - AV node 4–5
 - baseline recordings 47, 51–52
 - bradyarrhythmias 14–15
 - Brugada syndrome 204
 - bundle branch block 92
 - bypass tract localization 241–243, 252–253
 - coupling intervals 40–41
 - cycle lengths 40
 - delta waves 139–141, 242–243
 - directionality 10, 11–12
 - idiopathic left ventricular tachycardia 202–203
 - intraatrial reentry 114, 164, 165
 - multifocal atrial tachycardia 109
 - pause-dependent ventricular tachyarrhythmias 198–201
 - PR interval 4–5, 10, 11
 - P wave 10, 11
 - QT intervals 10, 12
 - reentrant ventricular arrhythmias 173–175, 255–256, 266–268
 - sinoatrial nodal reentry 114, 164, 165

- ST segment 10, 12
- syncope 343–345
- T wave 10, 12
- ventricular brillation 176
- electrode catheters
 - construction 41–42
 - insertion and positioning
 - atrioventricular junction
 - ablation 233–234
 - bypass tract ablation
 - 246–253
 - principles 47–51
 - reentrant atrioventricular
 - node ablation 237–241
 - supraventricular tachycardias
 - 116–117
- electroencephalograms (EEG),
 - syncope 344
- electrolyte levels,
 - pause-dependent
 - triggered activity 197
- emergency equipment 45–46
- encainide 27–29
- EnSite Array system 228–230
- EnSite NavX system 228, 230
- entrainment mapping 271–274
- epicardial sinus 259, 276–278
- equipment for studies 41–42,
 - 45–46
- equipment for treatment
 - 221–231
- ERP *see* effective refractory
 - periods
- escape pacemakers 15
- evaluation
 - antiarrhythmic drugs 61
 - automaticity 53
 - baseline recordings 51–52
 - basic protocol 51
 - bradycardia 63–106
- atrioventricular block
 - extrastimulus technique
 - 87–91
 - rst-degree 76–77, 83–84
 - incremental pacing 91–93
 - second-degree 77–79,
 - 84–86
 - third-degree 79–80, 86
- atrioventricular node 75–93
- bundle branch block 93–97
- Mobitz-type I block 77–79,
 - 84–85
- Mobitz-type II blocks
 - 77–79, 85–86
- SACT 70–73, 74
- SNRT 66–70, 74
- bypass tracts
 - ablation procedures
 - 246–253
- electrocardiograms
 - 241–243
- intracardiac electrograms
 - 244–246
- cardiac resynchronization
 - therapy 326–327,
 - 329–331
- catechol-dependent triggered
 - activity 200–202
- clinical methodology 347–353
- complications 62
- conduction velocities 54–55,
 - 57–58
- cumulative risk 62
- His bundle conductivity
 - 54–55
- intrinsic heart rate 73–74
- pause-dependent triggered
 - activity 197–201
- reentrant arrhythmias 58–61,
 - 129–196

- evaluation (*Continued*)
 - preoperative testing
 - 194–196
 - refractory period 55–58
 - structural heart disease 353
 - supraventricular tachycardia
 - 107–166
 - atrial brillation 151–153, 159–163, 164
 - atrial utter 151–153, 157–159, 164
 - atrioventricular nodal reentry 129–138, 164
 - bypass tract-mediated 138–155, 164, 165
 - classifications 108–116
 - intraatrial reentry 155–156, 164, 165
 - invasive testing requirements 163–166
 - principles 118–129
 - sinoatrial node reentry 156–157, 164, 165
 - syncope
 - bradyarrhythmias 334–335
 - methodologies 338–341, 342–345
 - supraventricular tachycardia 335–336
 - tilt-table testing 340–341
 - vasodepressor 338–342
 - ventricular brillation 177–179
 - ventricular tachycardia 336–338
 - therapeutic end points 353–354
 - treatment plans 354–357
 - ventricular arrhythmias
 - 167–205
 - automatic 198–202
 - brillation 176–180
 - functions 180
 - inducibility 191–194
 - initiation 180–187
 - intravenous adenosine 178
 - preoperative testing 194–196
 - reentrant 169–198
 - termination 187–189
 - treatment 194–196, 205–220
 - unusual 202–205
 - evidence-based approaches, ICDs 212–220
 - exercise-related syncope 337, 344
 - excitability 6, 8–9
 - exit block, sinoatrial node 70–73
 - extrastimulus technique
 - atrioventricular block 91–93
 - bypass tract-mediated reentry termination 146
 - principles 44–45
 - reentrant ventricular tachycardia 181–188
- f**
- fainting *see* syncope
 - false positives 185–186
 - fasciculoventricular bypass tracts 154
 - femoral vein catheterization 47–48
 - brillation
 - atrial
 - ablation therapy 279–299
 - antiarrhythmic drugs 160–163
 - brady-tachy syndrome 65–66

- diagnosis 114–115, 151–153, 159–160
 - pacemakers 161
 - rate control 161–163
 - rhythm control 160–161, 162–163
 - supraventricular tachycardia 151–153, 159–163
 - treatment 160–163
 - ventricular 168, 176–180, 188
 - evaluation 168, 176–180, 188
 - rst-degree AV block 14, 76–77, 83–84, 335
 - ecainide 29, 150, 160
 - uoroscopic imaging 48–49
 - utter, brady-tachy syndrome 65–66
 - focal atrial tachycardia ablation 254
 - FRP *see* functional refractory periods
 - functional refractory periods (FRP) 57, 87–88
- g**
- generation of transmembrane potential 5–11
- h**
- heart block
 - see also* atrioventricular block
 - classifications 14–16
 - inadvertent 231
 - permanent pacemakers 96
 - heart rates, cycle lengths 40
 - hemodynamically non-tolerated ventricular tachycardia, ablation therapy 274–277
 - hemodynamic stabilization, cardiac resynchronization therapy 322
 - h gates 25–29
 - His bundle
 - anatomy 4–5
 - atrioventricular junction ablation 234
 - bypass tracts 138–139, 252–253
 - conduction velocity measurement 54–55
 - electrograms 50, 54–55, 82–93
 - His–Purkinje system
 - anatomy 4–5
 - bradycardia 76, 85–86, 93–96
 - bundle branch block 93–96
 - extrastimulus technique 87–88, 90–91
 - incremental pacing 91
 - bundle branch block 93–97, 148, 202–204
 - bypass tract/macroeentrant tachycardia 113–114
 - electrode placement 50–51
 - rst-degree blocks 83
 - heart block 14–15
 - Mobitz type II block 85–86
 - second-degree blocks 85
 - syncope 335
 - third-degree blocks 86
 - H spikes 50, 54–55
 - HV intervals 50, 54–55
- i**
- ibutilide 160–161
 - ICD *see* implantable cardioverter–defibrillators
 - ICE *see* intracardiac echocardiography

- idiopathic left ventricular
 - tachycardia 202–203, 262–264
- IHR *see* intrinsic heart rate
- Immediate Risk Stratification Improves Survival (IRIS) trial 214–216
- implantable cardioverter–defibrillators (ICD) 189, 209–220
 - see also* pacemakers
 - bradyarrhythmias 96–106
 - Brugada syndrome 204
 - complications 210–211
 - evidence-based approaches 212–220
 - ischemic cardiomyopathy 215, 217–219
 - non-ischemic cardiomyopathy 216–219
 - overview 209–210
 - post-myocardial infarction 215–216
 - preoperative testing 194–196
 - primary prevention trials 212–216
 - programming 210
 - secondary prevention trials 212–213
 - subcutaneous 211
 - vs. antiarrhythmic drugs 189
 - wireless monitoring 211–212
- implantation, cardiac
 - resynchronization therapy 327–328
- inapparent disorders 86–93
- inappropriate rate tracking 103
- inappropriate sinus tachycardia (IST) 109–111, 114
- incremental pacing
 - atrioventricular block 91–93
 - bypass tract-mediated reentry initiation 146
 - principles 44
 - reentrant ventricular tachycardias 181–188
 - Wenckebach cycle length 91
- infranodal block 81
 - see also* distal block
- initiation
 - atrioventricular nodal reentry 131–133
 - bypass tract-mediated supraventricular reentry 143–146
 - intraatrial reentrant tachycardia 155–156
 - macroreentry 143–146
 - principles 19, 21, 58–59
 - reentrant ventricular tachycardias 180–187
 - SA nodal supraventricular tachyarrhythmias 156–157
 - tachycardia zones 120
 - triggered activity 22
- innervation of parasympathetic/sympathetic fibers 11
- insertion of electrodes 47–51
 - atrioventricular junction ablation 233–234
 - bypass tract ablation 246–253
 - principles 47–51
 - supraventricular tachycardias 116–117
- interpretation
 - atrioventricular tests 83–93
 - sinoatrial tests 74

- intraatrial conduction intervals 55
 - intraatrial reentrant tachycardia 114, 155–156, 158, 164, 165
 - intracardiac echocardiography (ICE) 282
 - intracardiac electrograms
 - antiarrhythmic drug evaluation 61
 - baseline recordings 47, 51–52, 116–117
 - basic protocol 51
 - bradycardia
 - atrioventricular block 75–93
 - extrastimulus technique 91–93
 - rst-degree 76–77, 83–84
 - inapparent disturbances 86–93
 - Mobitz-type I block 77–79, 84–85
 - Mobitz-type II block 77–79, 85–86
 - overt disturbances 83–86
 - second-degree 77–79, 84–86
 - third-degree 79–80, 86
 - bundle branch block 93–96
 - sinoatrial block
 - interpretation 74
 - SACT measurement 70–73
 - SNRT measurement 66–70
 - bypass tracts 244–246
 - complications 62
 - conduction velocities 54–55, 57–58
 - cumulative risk 62
 - electrode positioning 47–51
 - equipment 41–42, 45–46
 - extrastimulus technique 44–45, 91–93
 - incremental pacing 44
 - methodologies 51–61
 - overdrive suppression 53
 - pacing 43–45
 - principles 42–43
 - recording 60–61
 - reentrant supraventricular tachycardia 116–159
 - refractory periods 55–58
 - intravenous adenosine 178
 - intraventricular conduction delay (IVCD) 94
 - intrinsic heart rate (IHR) 73–74
 - ion channels
 - antiarrhythmic drugs 25–29
 - automaticity 8–9
 - depolarization 5, 6–7
 - IRIS *see* Immediate Risk
 - Stratification Improves Survival trial
 - ischemic cardiomyopathy
 - diagnosis 353
 - implantable cardioverter–defibrillators 215, 217–219
 - isolated pulmonary veins, repeat procedures 293–295
 - isoproterenol 152, 181, 183–184
 - IST *see* inappropriate sinus tachycardia
 - IVCD *see* intraventricular conduction delay
- j**
- Jervell–Lange–Nielson syndrome 202

junction boxes 45

k

Koch's triangle 236–237

l

laboratory requirements 45–46

LBBB *see* left bundle branch block

leadless pacemakers 104

lead placement, cardiac
resynchronization
therapy 330–331

left atria, electrode placement 48

left bundle branch block (LBBB)
95–97

bundle branch reentry
203–204

Mahaim tracts 248–250

outflow tract ventricular
tachycardia 203

posterior septal bypass tracts
251

left-sided atrial flutter

ablation therapy 309–317

anterior wall-related 315–316

de novo 316–317

peri-mitral 311–313

roof-dependent 313–315

left-sided bypass tracts 147, 242,
246–247

left-sided pulmonary vein isolation
284–285

left ventricle outflow tract (LVOT)

anatomy 258–259

mapping 260–261

left ventricles, electrode placement
48, 49–50

left ventricular su 262i.7894 -1.2638 TD lid5.2(tr)58.9(1)-.3(t)nia8(200.7(258–259)]TJ 0 -1.2628 TD -)-.2(r)58
ap(g01 Tc [5.1f)-1am.4(t)--32942-7.4(i.7894 -1.2638 TD 2410013-1001.u 22-10)-1001.-32942-7.4(i2TJ 0 -1.2638

- multiple bypass tracts
 - 154–155
- myocardial involvement 148
- pacemakers 150
- P wave/QRS complex
 - relationships 148
- QRS complexes 143–144, 148
- retrograde conduction
 - 143–148, 150
- termination 146
- treatment 148–155
- MADIT I/II *see* Multicenter
 - Automatic De brillation
 - Implantation Trials
- magnetic eld mapping 226–228
- Mahaim tracts 138–139, 154,
 - 248–250
- mapping
 - atrial brillation ablation 282
 - bypass tracts
 - electrocardiograms
 - 241–243
 - intracardiac electrograms
 - 244–246
 - electrical eld systems 228
 - focal atrial tachycardias 254
 - magnetic eld systems
 - 226–228
 - noncontact systems 228–230
 - principles 60–61
 - reentrant atrioventricular node
 - ablation 238–239
 - systems 225–231
- measurement
 - atrioventricular block 75–80
 - conduction velocities 54–55,
 - 57–59
 - refractory periods 55–58
 - sinoatrial conduction time
 - 70–73
 - sinus node recovery time
 - 66–70
 - ventricular dyssynchrony 331
- mechanisms
 - antiarrhythmic drugs 25–29
 - atrial utter/ brillation
 - 157–159
 - atrioventricular nodal reentry
 - 129–131
 - bradyarrhythmias 13–16
 - bypass tract-mediated
 - macroreentry 138–143
 - intraatrial reentrant tachycardia
 - 155–157
 - syncope 333–341
 - tachyarrhythmias 16–23
 - ventricular tachyarrhythmias
 - 169
- metabolic causes 17, 32–33, 197
- mexiletine 29
- m gates 25–26
- midseptal bypass tracts 242,
 - 252–253
- mitral valve prolapse 205, 259,
 - 262
- Mobitz-type I blocks 77–79,
 - 81–82, 84–85, 91
- Mobitz-type II blocks 77–79,
 - 81–82, 85–86
- modes of therapeutic pacing
 - 98–101
- modi ed Seldinger technique 47
- Multicenter Automatic
 - De brillation
 - Implantation Trial
 - (MADIT I/II) 213–215
 - Multicenter Unsustained
 - Tachycardia Trial
 - (MUSTT) 214–215
- multifocal atrial tachycardia 109

- multiple bypass tracts 154–155
- MUSTT *see* Multicenter Unsustained Tachycardia Trial
- myocardial infarctions
 - automatic ventricular arrhythmias 196–197
 - implantable
 - cardioverter–de brillator installation 215–216
 - risk of reentrant ventricular tachyarrhythmias 173–174
- myocardium
 - see also* ischemic cardiomyopathy; nonischemic cardiomyopathy
 - secondary pacemaker cells 8–9, 15, 79, 81
 - structural heart disease 266–274, 353
 - supraventricular reentrant tachycardia 135–136, 148
 - ventricular reentrant tachyarrhythmias 171–174
- n**
- nomenclature, permanent pacemakers 97
- noncontact mapping 228–230
- noninducibility 184, 191–194
- noninvasive differentiation, AV conduction disorders 81–82
- non-ischemic cardiomyopathy
 - implantable cardioverter–de brillators 216–219
 - reentrant ventricular tachyarrhythmias 171–174, 275–276
- nonpharmacologic therapies 25–33
 - see also* ablation therapy; device therapy
 - device therapies 35
 - reentrant ventricular tachycardias 194–196
 - reversible etiologies 33–34
- normal sinus rhythm 64
- nurses 46
- o**
- optimization of cardiac resynchronization therapy 329–331
- outflow tract ventricular tachycardia 203, 258–262
- overdrive suppression 53, 66–70
- overt atrioventricular conduction disturbances 83–86
- p**
- pacemakers 96–106
 - see also* implantable cardioverter–de brillators; sinoatrial node
 - atrial brillation 161
 - atrioventricular dissociation 79–80
 - atrioventricular junction ablation 234
 - bradyarrhythmias 96–106
 - cardiac resynchronization therapy 95, 97, 100–101, 319–332

- clinical studies 323–326
- effects 322–323
- implantation 327–328
- indications 326–327
- optimization 329–331
- principles 320–322
- complications 101–105, 210–211
- coupling intervals 40–41
- decisioning 81, 105–106
- distal block 79, 81
- evidence-based approaches 212–220
- indications 96–97
- leadless 104
- macroreentrant tachycardias 150
- modes 98–101, 105–106
- mode switching 103
- nomenclature 97
- overview 209–210
- preoperative testing 194–196
- principles 35
- programming 210
- secondary cells 8–9, 15, 79, 81
- sensitivity 102
- sinus bradycardia 13
- wireless monitoring 211–212
- pacemaker syndrome 101
- pacemaker tachycardia 101–103
- pace mapping, ventricular tachycardia 258, 271–274
- pacing
 - see also* extrastimulus technique; incremental pacing; programmed stimulation
 - AAI/VVI modes 98–99
 - atrioventricular junction ablation 234
- cardiac resynchronization therapy 95, 97, 100–101, 319–332
- common device modes 98–101
- DDD modes 99–100
- overdrive suppression 53
- principles 43–45
- reentrant arrhythmia evaluation 58–60
- SACT measurements 70–73
- SNRT measurement 68–70
- ventricular tachycardia
 - reentrant induction 180–187
 - reentrant termination 187–189
- papillary muscle, ventricular tachycardia 259
- paraseptal bypass tracts 250–251
- parasympathetic signaling 11, 58
- pathways
 - antiarrhythmic drug effects 61
 - reentry 18–21
 - refractory period deviations 58–60
- patients
 - basic protocol 51–52
 - catheterization 47–51
 - complications 62
 - electrocardiogram procedures 51–62
 - preparation 46–47
 - psychological preparation 47
 - serial drug testing 61
- pause-dependent triggered activity, evaluation 197–201
- perforation, risk 231

- peri-mitral utter, ablation therapy 311–313
- permanent pacemakers *see* cardiac resynchronization therapy; implantable cardioverter–de brillators; pacemakers
- personnel requirements 46
- pharmacologic therapies
 - see also* antiarrhythmic drugs
 - atrial brillation 160–163
 - classi cation 27–29
 - discontinuation 33–34
 - e ects 29–31
 - evaluation 62
 - mechanisms 25–27
 - patient evaluation 61
 - proarrhythmia 31–32
 - serial testing 62
 - side e ects 34
 - toxicity 32–33
- phases of cardiac action potentials
 - see* depolarization; refractory period; repolarization; resting phase
- phenytoin 29
- physical setup 41–42, 45–46
- polymorphic ventricular tachycardia
 - catecholaminergic 61, 200–202, 205
 - torsades de pointes 23, 32–33, 197–201
- positioning of electrodes
 - atrioventricular junction
 - ablation 233–234
 - bypass tract ablation 246–253
 - principles 47–51
 - reentrant atrioventricular node
 - ablation 238–241
 - supraventricular tachycardias 116–117
- posterior septal bypass tracts 242, 250–251
- post-operative electrograms, pulmonary vein isolation 288–289
- post-ventricular atrial refractory period (PVARP) 102–103
- preexcitation, bypass tracts 139–141
- premature impulses
 - reentry
 - initiation 58–59
 - interactions 58–60
 - termination 59–60
 - testing principles 43–44
- premature ventricular complexes (PVCs)
 - see also* ventricular tachycardia
 - ablation therapy 255–278
 - bundle branch reentry 264–266
 - epicardial sinus 259, 276–277
 - hemodynamically non-tolerated 274–277
 - idiopathic left ventricular tachycardia 262–264
 - out ow tract 259–262
 - structural heart disease 266–274
 - activation mapping 256–258, 270
 - anatomical considerations 258–259

- non-ischemic cardiomyopathies 275–276
 - pace mapping 258, 271–274
 - preoperative testing, reentrant ventricular tachycardias 194–196
 - preparation of patients 46–47
 - primary prevention trials, ICDs 212–216
 - PR intervals
 - anatomy 4–5, 10, 11
 - atrioventricular nodal bypass tracts 153
 - measurement 55
 - proarrhythmia 31–32, 160–161
 - programmable stimulators 45
 - programmed stimulation
 - see also* pacing
 - principles 43–45, 58–60
 - ventricular arrhythmias 180–190
 - initiation 180–187
 - termination 187–189
 - programming, implantable cardioverter–de brillators 210
 - propafenone 27–29, 150, 160–161
 - propagation
 - action potentials 7, 11–12
 - bradyarrhythmias 14–16
 - proximity effects, bypass tracts 139–141
 - psychological preparation of patient 47
 - pulmonary vein isolation (PVI) 281–298
 - blanking periods 291
 - carina 286, 287
 - cryo ablation 295–298
 - drug testing 289–290
 - left-sided 284–285
 - post-operative electrograms 288–289
 - preparation 281
 - repeat procedures 290–295
 - right-sided 285–287
 - waiting period 287–289
 - Purkinje bres
 - anatomy 4–5
 - bundle branch block 93–96
 - bypass tracts 138–139
 - His-bundle electrograms 54
 - Mobitz type II block 76, 85–86
 - stereotypical action potential 9
 - PVARP *see* post-ventricular atrial refractory period
 - PVCs *see* premature ventricular complexes
 - PVI *see* pulmonary vein isolation
 - P waves
 - atrial utter and brillation 114–115, 164
 - atrioventricular nodal reentry 136
 - bypass tract-mediated tachycardia 148
 - intraatrial reentry 114
 - macroreentrant tachycardia 148
 - properties 10, 11
- q**
- QRS complexes
 - anatomy 10, 11–12
 - atrial utter and brillation 164
 - atrioventricular nodal reentry 136

QRS complexes (*Continued*)

- bypass tract-mediated tachycardia 143–144, 148
 - directionality 10, 11–12
 - duration measurement 55
 - idiopathic left ventricular tachycardia 202–203
 - intraatrial reentry 114
 - intraventricular conduction delay 94
 - macroreentrant tachycardia 148
 - reentrant ventricular tachyarrhythmias 173–176
 - sinoatrial nodal reentry 114
 - ventricular tachycardia 175–176
- QT intervals
- anatomy 10, 12
 - catechol-dependent triggered activity 202
 - pause-dependent ventricular tachyarrhythmias 198–199
- quadripolar electrode catheter construction 41–42
- quiescence 8, 10

r

- RACE trial 162–163
- radiofrequency (RF) ablation
- see also* ablation therapy complications 231 pulmonary vein isolation 281–295, 297–298 technology 223–224 utilization 224

- rapid sodium channels
- class I drugs 27–29
 - depolarization 6–7
 - mode of action 25–26
- rate control, atrial brillation 161–163
- rate tracking pacemaker errors 103
- RBBB *see* right bundle branch block
- reconnected pulmonary vein ablation 291–293
- recording
- bipolar con guration 42
 - principles 39–45
 - reentrant arrhythmias 60–61
- recovery time, sinoatrial node 66–70
- recurrent arrhythmias, reversible etiologies 32–33
- reentrant arrhythmias
- see also* macroreentrant tachycardia; reentrant supraventricular tachycardia; reentrant ventricular tachycardia; reentry
 - evaluation 58–61, 129–196
 - programmed stimulation 58–60
 - recording 60–61
 - serial drug testing 61
- reentrant supraventricular tachycardia 111–163
- see also* atrial brillation; atrial utter; macroreentrant tachycardia
 - ablation therapy 233–253
 - atrioventricular junction 233–234

- atrioventricular node reentry
 - 234–241
- bypass tracts 241–253
- AV nodal 112–113, 129–138, 164–165
- bypass tract-mediated
 - 113–114, 138–155, 164, 165
- classi cations 111–116
- diagnosis 116–129, 164–165
- electrode insertion 116–117
- intraatrial 114, 155–156, 165
- localization 118–125, 146–148, 151
- SA nodal 114, 156–157, 164, 165
- syncope 335–336
- reentrant ventricular tachycardia
 - 169–198
- ablation therapy 255–277
 - bundle branch reentry 264–266
 - complications 277
 - epicardial sinus 259, 276–277
 - hemodynamically non-tolerated 274–277
 - idiopathic left ventricular tachycardia 262–264
 - non-ischemic cardiomyopathies 275–276
 - structural heart disease 266–274
- activation mapping 256–258, 270
- antiarrhythmic drugs
 - 189–190, 192–194
- bundle branches 264–266
- clinical characteristics 175–180
- degeneration 188
- diagnostic methodology 180–190
- “dunk-tank model” 192–194
- electrocardiograms 173–175, 255–256, 266–268
- entrainment mapping 271–274
 - brillation 176–180
- idiopathic left ventricular tachycardia 262–264
- inducibility 191–194
- initiation 180–187
- noninducibility 184, 191–194
- pace mapping 258, 271–274
- preoperative testing 194–196
- QRS complexes 173–176
- risk factors 171–174
- sudden death 167–169, 172–173, 204–205
- syncope 177–179, 336–338
- termination 187–189
- treatment 194–196
- reentry
 - antiarrhythmic drugs 29–33, 61
 - concealed conduction 143–148
 - conduction delays 118–120
 - congenital 20
 - disorder acquisition 20–21
 - entrainment mapping 271–274
 - initiation 19, 21, 58–59
 - mapping, principles 60–61
 - mechanisms 17–21
 - pace mapping 258, 271–274
 - prerequisites 18–19

- reentry (*Continued*)
 - proarrhythmia 31–32
 - supraventricular tachycardia 129–131, 138–143, 155–156
 - surgical therapies, principles 34–35
 - syncope 336–337
 - tachycardia zones 21
 - termination 20–21, 59–60
 - ventricular tachycardia 169–198
- refractory period
 - antiarrhythmic drugs 29–32
 - cycle length effects 57–58
 - evaluation 55–58
 - macroreentrant tachycardia 148–150, 152–153
 - principles 6, 7–8
 - proarrhythmia 31–32
 - reentry 18–21
- relative refractory periods (RRP) 56, 58–60, 87–88
- repeat procedures, atrial
 - brillation ablation 290–295
- repetitive monomorphic
 - ventricular tachycardia 203
 - see also* outflow tract ventricular tachycardia
- repolarization
 - anatomy 7–8
 - ECGs 12
- resting heart rates 64–65
- resting phase
 - antiarrhythmic drugs 29–30
 - cellular activity 8–9
- resting transmembrane potentials 5
- retrograde conduction 143–148, 150
- return intervals 71–72
- reverse remodeling, cardiac
 - resynchronization therapy 323
- reversible etiologies 32–33
- RF *see* radiofrequency
- rhythm control 160–161, 162–163
- right atria, electrode placement 48
- right bundle branch block (RBBB) 94–95, 202–203, 251
- right-sided atrial flutter, ablation therapy 306–309
- right-sided bypass tracts 147, 242, 247–248
- right-sided pulmonary vein isolation 285–287
- right ventricle outflow tract (RVOT) 258–260
- right ventricles
 - dysplasia 203
 - electrode placement 49
- risk factors
 - atrial brillation 298
 - Brugada syndrome 204
 - direct current ablation 222
 - radiofrequency ablation 231
 - reentrant ventricular tachyarrhythmias 171–174
 - sudden death 172–174, 204–205
- roof-dependent left atrial flutter ablation 313–315
- RRP *see* relative refractory periods

- S**
- SA *see* sinoatrial
 - SACT *see* sinoatrial conduction time
 - sawtooth patterns 114–115
 - scar tissue, reentry 20–21
 - SCD-HeFT *see* Sudden Cardiac Death in Heart Failure Trial
 - secondary pacemaker cells 8–9, 15, 79, 81
 - secondary prevention trials, ICDs 212–213
 - second-degree atrioventricular block 14, 15, 77–80, 84–86
 - sedation 47
 - sensitivity
 - pacemakers 102
 - radiofrequency ablation 224
 - serial drug testing 61–62
 - shapes of cardiac action potentials 5, 9–12, 25–27
 - sick sinus syndrome *see* sinus bradycardia
 - side effects, antiarrhythmic drugs 34
 - signal-averaged
 - electrocardiograms 173–175
 - sinoatrial conduction time (SACT) 70–73
 - sinoatrial (SA) node
 - anatomy 3–4, 64
 - automaticity 8–9, 66–70
 - bradyarrhythmias 13–14, 64–65, 73, 96
 - bradycardia evaluation 64–74
 - bypass tract proximity effects 139–141
 - conduction times 70–73
 - dysfunctions 64–66
 - exit block 70–73
 - brosis 65
 - inappropriate sinus tachycardia 110
 - intrinsic heart rate 73–74
 - overdrive suppression 53
 - reentrant tachycardia 114, 156–157, 164, 165
 - SACT measurement 70–73, 74
 - SNRT measurement 66–70, 74
 - stereotypical action potential 9
 - syncope 334–335
 - tachyarrhythmias 16–17
 - test interpretation 74
 - sinus electrode placement 48–49
 - sinus node recovery time (SNRT) 66–70, 74
 - slow pathway ablation,
 - atrioventricular node 237–241
 - SNRT *see* sinus node recovery time
 - sodium channels
 - class I drugs 27–29
 - depolarization 6–7
 - sotalol 29
 - structural heart disease
 - entrainment mapping 271–274
 - evaluation 353
 - ventricular tachycardia, ablation therapy 266–274
 - ST segment
 - anatomy 10, 12
 - Brugada syndrome 204
 - studies
 - see also* diagnosis; evaluation
 - amiodarone 207–208
 - antiarrhythmic drugs 61

- studies (*Continued*)
 - atrial brillation treatments 162–163
 - atrioventricular block 75–93
 - automaticity evaluation 53
 - baseline recordings 51–52, 116–117
 - basic protocol 51
 - bradycardia 63–106
 - bundle branch block 93–96
 - bypass tracts
 - electrocardiograms 241–243
 - intracardiac electrograms 244–246
 - cardiac electrophysiology evaluation 52–61
 - cardiac resynchronization therapy 323–326
 - complications 62
 - conduction velocities 54–55, 57–58
 - cumulative risk 62
 - equipment 41–42, 45–46
 - extrastimulus technique 44–45
 - incremental pacing 44
 - laboratory requirements 45–46
 - pacing 43–45
 - patient preparation 46–47
 - positioning of electrodes 47–51
 - principles 39–62
 - programmed stimulation 43–44
 - psychological preparation 47
 - recording 39–45, 60–61
 - reentrant disorders, principles 58–60
 - refractory periods 55–58
 - sinoatrial disorders 64–74, 334–335
 - supraventricular tachycardia 107–166
- subcutaneous implantable cardioverter–de brillators 211
- Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) 214–215
- sudden death
 - atrioventricular junction ablation 234
 - preventative treatment plans 356–357
 - risk factors 172–174
 - “survivors” 177–178
 - syncope 334–335, 336–337, 344–345
 - ventricular arrhythmias 167–169, 172–173, 204–205
- sudden unexpected nocturnal death syndrome (SUNDS) 204
- SUNDS *see* sudden unexpected nocturnal death syndrome
- superior vena cava, anatomy 3–4
- supraventricular tachycardia 107–166
 - see also* atrial brillation; atrial utter
 - ablation therapy 233–254
 - atrioventricular junction 233–234
 - atrioventricular node reentry 234–241

- bypass tracts 241–253
- focal atrial tachycardia 254
- antiarrhythmic drugs 111
- atrioventricular node reentrant 112–113, 129–138
 - activation patterns 134–135
 - diagnosis 164–165
 - initiation 131–133
 - mechanisms 129–131
 - properties 129–131, 136
 - P wave/QRS complexes 136
 - termination 133–134
 - treatment 137–138
- automatic, classi cation 108–111
- bypass tract-mediated 113–114, 138–155
 - activation patterns 146–148
 - diagnosis 118, 146–148, 151, 164, 165
 - initiation 143–146
 - localization 118, 146–148, 151
 - mechanisms 138–143
 - termination 146
 - treatment 148–155
- conduction delays 118–125
- coupling intervals 120
- di erential diagnosis 163–166, 178–179
- digitalis toxicity 108–109
- electrode insertions 116–117
- evaluation
 - classi cations 108–116
 - di erential diagnosis 163–166
 - principles 118–129
- inappropriate sinus tachycardia 109–111
- intraatrial reentry 114, 155–156
- intravenous adenosine 178
- mechanisms 129–131, 138–143, 155–156
- multifocal atrial tachycardia 109
- reentrant 111–163
 - atrial brillation 114–115, 151–153, 159–163, 164
 - atrial utter 114–115, 151–153, 157–159, 164
 - AV nodal 112–113, 164–165
 - bypass-tract mediated 113–114, 164, 165
 - classi cation 111–116
 - general diagnostic principles 116–129
 - intraatrial 114, 155–156, 164, 165
 - localization 118–125, 146–148, 151
 - myocardial involvement 135–136, 148
 - SA nodal 114, 156–157, 164, 165
- sinoatrial node reentrant 114, 156–157, 164, 165
- syncope 335–336
- treatment
 - atrial brillation 160–163
 - atrial utter 159
 - atrioventricular node reentrant 137–138
 - inappropriate sinus 111
 - macroreentrant circuits 148–155
 - sinoatrial nodal 157
- surgical therapies
 - complications 104–105

- surgical therapies (*Continued*)
 - macroreentrant
 - supraventricular tachycardia 155
 - principles 34–35
 - sympathetic bers, innervations 11
 - sympathetic signaling, conduction velocities 58
 - symptom relief, treatment plans 355–356
 - symptoms, atrioventricular block 75
 - syncope 333–345
 - bradyarrhythmias 334–335
 - brady-tachy syndrome 66
 - causes 333–342
 - electrocardiograms 343–345
 - electroencephalograms 344
 - evaluation, ventricular
 - brillation 177–179
 - permanent pacemakers 96
 - sudden death 334–335, 336–337, 344–345
 - supraventricular tachycardia 335–336
 - tachyarrhythmias 335–338
 - tilt-table testing 340–341
 - vasodepressor 338–342
 - ventricular tachycardia 336–338
- t**
 - tachyarrhythmias 16–23, 107–220
 - see also* supraventricular tachycardia; ventricular tachycardia
 - afterdepolarization 21–23
 - automaticity 16–17, 53
 - mechanisms 16–23
 - metabolic causes 17
 - pacemaker-related 101–103
 - reentry mechanisms 17–21
 - syncope 335–338
 - triggered activity 21–23
 - tachycardia zones 21, 118, 120
 - see also* localization
 - technology, ablation therapy 221–224
 - termination
 - atrioventricular node
 - supraventricular tachycardia 133–134
 - bypass tract-mediated
 - supraventricular tachycardia 146
 - principles 20–21, 59–60
 - sinoatrial nodal supraventricular tachyarrhythmias 157
 - ventricular tachycardias 187–189
 - testing *see* diagnosis; evaluation; studies
 - therapeutic end points 353–354
 - third-degree atrioventricular block 14, 15, 79–80, 86
 - tilt-table testing 340–341, 344
 - time measurement principles 39–41
 - tissue contact, radiofrequency ablation 224
 - tocainide 29
 - torsades de pointes 23, 32–33, 197–201
 - toxicity
 - antiarrhythmic drugs 32–33
 - digitalis 108–109, 111
 - transcatheter ablation 221–318
 - see also* ablation therapy

- atrial brillation 279–299
- atrial utter 299–318
- complications 231
- cryo, technology 224
- direct-current shocks, technology 222
- electrical eld mapping 228
- intraatrial reentrant tachycardia 156
- magnetic eld mapping 226–228
- mapping systems 225–231
- noncontact mapping 228–230
- radiofrequency energy complications 231 technology 223–224
- supraventricular tachycardia 233–254
- technology 221–224
- ventricular tachycardia 255–278
- transitional zone, atrioventricular node 233–238
- transmembrane potentials
 - antiarrhythmic drugs 25–27
 - depolarization 6–7
 - generation 5–11
 - repolarization 7–8
 - resting 5, 8–9
- transseptal puncture, atrial brillation 283
- treatment
 - ablation therapy 221–318
 - atrial brillation 279–299
 - carina 286, 287
 - cryoballoons 295–298
 - drug testing 289–290
 - history 279–280
 - left-sided 284–285
 - mapping 282
 - post-operative electrograms 288–289
 - preparation 281
 - pulmonary vein isolation 281–298
 - repeat procedures 290–295
 - right-sided 285–287
 - substrate modification 298
 - transseptal puncture 283
 - atrial utter 299–318
 - anterior wall left-sided 315–316
 - CTI-dependent 303–306
 - de novo* left-sided 316–317
 - left-sided 309–317
 - non-CTI-dependent 306–317
 - peri-mitral 311–313
 - right-sided 306–309
 - roof-dependent left-sided 313–315
 - mapping systems 226–230
 - supraventricular tachycardia 233–254
 - atrioventricular junction 233–234
 - atrioventricular node reentry 234–241
 - bypass tracts 241–253
 - focal atrial tachycardia 254
 - technology 222–224
 - ventricular tachycardia 255–278
 - activation mapping 256–258, 270

- treatment (*Continued*)
 - bundle branch reentry
 - 264–266
 - complications 277
 - epicardial sinus 259, 276–278
 - hemodynamically
 - non-tolerated 274–277
 - idiopathic left ventricular tachycardia 262–264
 - non-ischemic
 - cardiomyopathies 275–276
 - pace mapping 258, 271–274
 - structural heart disease 266–274
- atrial brillation 160–163
 - cryo ablation 295–298
 - mapping 282
 - radiofrequency ablation 281–295, 297–298
- atrial utter 159
 - CTI-dependent 303–306
 - non-CTI-dependent 306–317
- atrioventricular block 80–81
- atrioventricular node reentrant tachycardia 137–138
- bradycardia
 - permanent pacemakers
 - 96–106
 - complications 101–105
 - decisioning 81, 105–106
 - major indications 96–97
 - modes 98–101, 105–106
 - rate tracking 103
 - ventricular dyssynchrony 103–104
- cardiac resynchronization
 - 319–332
 - effects 322–323
 - implantation 327–328
 - indications 326–327
 - optimization 329–331
 - pacing modes 100–101
 - principles 95, 97, 320–322
 - studies 323–326
 - unresolved issues 328–329
- concepts 25–35
- focal atrial tachycardias 254
- implantable cardioverter–de brillators 189, 209–220
- bradyarrhythmias 96–106
- Brugada syndrome 204
- complications 210–211
- evidence-based approaches 212–220
- ischemic cardiomyopathy 215, 217–219
- non-ischemic
 - cardiomyopathy 216–219
- overview 209–210
- post-myocardial infarction 215–216
- preoperative testing 194–196
- primary prevention trials 212–216
- programming 210
- secondary prevention trials 212–213
- subcutaneous 211
- vs. antiarrhythmic drugs 189
- wireless monitoring 211–212

- inappropriate sinus tachycardia 111
 - macroreentrant
 - supraventricular tachycardia 148–155, 241–253
 - nonpharmacologic principles 33–35
 - pharmacologic therapies 25–33
 - classification 27–29
 - effects 29–32
 - mechanisms 25–27
 - proarrhythmia 31–32
 - toxicity 32–33
 - plans 354–357
 - sinoatrial nodal supraventricular tachyarrhythmias 157
 - sudden death prevention 356–357
 - symptom relief 355–356
 - therapeutic end points 353–354
 - vasodepressor syncope 338–342
 - ventricular tachycardia 194–196, 205–220, 255–278
 - treatment plans 354–357
 - triggered activity 197–202
 - antiarrhythmic drugs 32
 - catechol-dependent ventricular arrhythmia 61, 200–202, 205
 - concepts 21–23
 - pause-dependent ventricular arrhythmias 197–201
 - syncope 335–336
 - torsades de pointes 23, 32–33, 197–201
 - TU wave abnormalities 199–201
 - T waves 10, 12
- U**
- underlying causes
 - pause-dependent triggered activity 197–198
 - reversal 32–33
 - units 39
- V**
- valve prolapse, mitral 205, 259, 262
 - vasodepressor syncope 338–342
 - V defibrillations 50, 54–55
 - vein catheterization 47–48
 - vena cava 3–5
 - ventricles
 - bypass tract-mediated reentry 146–148
 - electrode placement 48–49
 - heart block 14–15
 - ventricular arrhythmia *see*
 - ventricular brillation;
 - ventricular tachycardia
 - ventricular dyssynchrony
 - bundle branch block 93–97, 148, 202–204, 248–250
 - cardiac resynchronization therapy 95, 97, 100–101, 103–104, 319–332
 - effects 322–323
 - implantation 327–328
 - indications 326–327
 - optimization 329–331
 - pacing modes 100–101
 - principles 320–322
 - studies 323–326
 - unresolved issues 328–329

- ventricular dyssynchrony
 - (Continued)
 - idiopathic left-sided 202–203
 - left bundle branch block
 - 95–97, 203–204
 - Mahaim tracts 248–250
 - measurement 331
 - right bundle branch block
 - 202–203
 - right-sided dysplasia 203
- ventricular escape mechanisms
 - 15
- ventricular brillation 168,
 - 176–180, 188
 - clinical characteristics
 - 176–180
 - electrocardiograms 176
 - syncope 177–179
- ventricular muscles, stereotypical
 - action potential 9
- ventricular tachycardia 167–220
 - see also* premature ventricular complexes
 - ablation therapy 209, 255–278
 - bundle branch reentry
 - 264–266
 - complications 277
 - epicardial sinus 259,
 - 276–278
 - hemodynamically
 - non-tolerated 274–277
 - idiopathic left ventricular
 - tachycardia 262–264
 - non-ischemic
 - cardiomyopathies
 - 275–276
 - structural heart disease
 - 266–274
 - activation mapping 256–258,
 - 270
- amiodarone 204, 207–208
- antiarrhythmic drugs 255
 - “conventional” treatment
 - 217–219
 - reentrant conditions
 - 189–190, 192–194
 - triggered activity 199, 202
 - vs. implantable cardioverter–
 - de brillators 189
- automatic 196–202
 - catechol-dependent 61,
 - 200–202, 205
 - evaluation 196–202
 - pause-dependent triggered
 - 197–201
- Brugada syndrome 204–205
- bundle branch block 202–204
- catechol-dependent triggered
 - activity 61, 200–202,
 - 205
- clinical characteristics
 - 175–176
- degeneration 188
- differential diagnosis
 - 178–179
- entrainment mapping
 - 271–274
- epicardial sinus 259, 276–278
- evaluation 167–205
 - antiarrhythmic drugs
 - 189–190, 192–194, 199,
 - 202, 217–219
 - automatic 196–202
 - brillation 176–180
 - functions 180
 - inducibility 191–194
 - reentrant 169–198
 - unusual 202–205
- evidence-based approaches
 - 212–220

- brillation 168, 176–180, 188
 - idiopathic left-sided 202–203
 - implantable cardioverter–de brillators 189, 209–220
 - complications 210–211
 - evidence-based approaches 212–220
 - overview 209–210
 - preoperative testing 194–196
 - programming 210
 - subcutaneous 211
 - wireless monitoring 211–212
 - inducibility 191–194
 - initiation, reentrant 180–187
 - initiation of reentry 180–187
 - intravenous adenosine 178
 - mechanisms 169
 - mitral valve prolapse 205
 - noninducibility 184, 191–194
 - out ow tract tachycardias 203
 - QRS complexes 175–176
 - reentrant 180–194
 - antiarrhythmic drugs 189–190, 192–194
 - “dunk-tank model” 192–194
 - inducibility 191–194
 - initiation 180–187
 - preoperative testing 194–196
 - termination 187–189
 - treatment 194–196
 - repetitive monomorphic 203
 - right-sided dysplasia 203
 - right ventricular dysplasia 203
 - risk factors 171–174
 - sudden death syndromes 167–169, 172–173, 204–205
 - syncope 336–338
 - termination 187–189
 - torsades de pointes 23, 32–33, 197–201
 - treatment 205–220
 - ablation therapy 209
 - antiarrhythmic drugs 189–190, 192–194, 199, 202, 217–219
 - implantable cardioverter–de brillators 209–220
 - preoperative testing 194–196
 - principles 206–209
 - underlying causes 197–198
 - verapamil 153
 - visibility, bypass tracts 138
 - VV intervals
 - cardiac resynchronization therapy 330
 - decisioning 105–106
 - inappropriate rate tracking 103
 - principles 98–99
- W**
- Wenckebach cycle length 91, 240
 - wireless monitoring, implantable cardioverter–de brillators 211–212
 - withdrawal, antiarrhythmic drugs 33–34
 - Wol –Parkinson–White syndrome 139–141

